Northwest (NWBO) Moves Sideways: Will It Jump Again?

Biotech stocks frequently depend on corporate updates and rarely move organically. Northwest stock isn’t an exception here. DCVax clinical trials have made NWBO trending among small-cap biotech stocks.

Two months ago the company released a presentation about the phase 3 clinical trial of the candidate for treating glioblastoma online. After seeing some positive results newcomers started buying the stock throughout the week. However, after surging to $1.91 NWBO drastically decreased to $0.76.

This week the stock is moving between $0.68 and $0.65. If any updates from DCVax clinical trials come out NWBO will surely move drastically either down or up. It would be the best idea to observe the stock on daily basis.